Business Description
Algernon Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA10639L1013
Share Class Description:
XTER:BTI: Class ACompare
Compare
Traded in other countries / regions
AGN.CanadaAGNPF.USAAGW0.Germany IPO Date
2016-02-08Description
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.26 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 45 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year FCF Growth Rate | 52.3 | |||||
| 3-Year Book Growth Rate | -63.1 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.04 | |||||
| Quick Ratio | 0.04 | |||||
| Cash Ratio | 0.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33.7 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -190.5 | |||||
| ROA % | -100.44 | |||||
| ROIC % | -80.44 | |||||
| ROCE % | -136.45 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.72 | |||||
| EV-to-EBIT | -0.59 | |||||
| EV-to-EBITDA | -0.6 | |||||
| EV-to-FCF | -1.25 | |||||
| Earnings Yield (Greenblatt) % | -169.49 | |||||
| FCF Yield % | -77.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Algernon Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.287 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 2.58446 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 2.58446 - 2.58446 | ||
| Shares Outstanding (Mil) | 21.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Algernon Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Algernon Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Algernon Pharmaceuticals Inc Frequently Asked Questions
What is Algernon Pharmaceuticals Inc(XTER:BTI)'s stock price today?
The current price of XTER:BTI is €2.58. The 52 week high of XTER:BTI is €2.58 and 52 week low is €2.58.
When is next earnings date of Algernon Pharmaceuticals Inc(XTER:BTI)?
The next earnings date of Algernon Pharmaceuticals Inc(XTER:BTI) is 2024-07-31 Est..
Does Algernon Pharmaceuticals Inc(XTER:BTI) pay dividends? If so, how much?
Algernon Pharmaceuticals Inc(XTER:BTI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers